-
公开(公告)号:US20150166569A1
公开(公告)日:2015-06-18
申请号:US14622446
申请日:2015-02-13
申请人: Genentech, Inc.
IPC分类号: C07D498/04 , C07D513/04 , C07D519/00 , C07D487/04
CPC分类号: C07D498/04 , C07D487/04 , C07D498/00 , C07D498/12 , C07D513/04 , C07D519/00
摘要: The invention relates to novel compounds of Formula I: wherein A1, A2, A3, A4, A5, A6, R2, R4, R5, R6, R7, R8 and subscripts m and n each has the meaning as described herein. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
摘要翻译: 本发明涉及式I的新化合物:其中A1,A2,A3,A4,A5,A6,R2,R4,R5,R6,R7,R8和下标m和n各自具有本文所述的含义。 式I化合物及其药物组合物可用于治疗观察到NF-kB信号传导的不期望或过度活化的疾病和病症。
-
2.
公开(公告)号:US20150038460A1
公开(公告)日:2015-02-05
申请号:US14515742
申请日:2014-10-16
申请人: Genentech, Inc.
IPC分类号: C07F7/08 , C07D491/107 , C07D403/14 , C07D405/14 , C07D413/14 , C07D403/04 , C07D487/04 , C07D491/08 , C07D401/14 , C07D417/14
CPC分类号: C07F7/0805 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D487/04 , C07D491/08 , C07D491/10 , C07D491/107
摘要: The invention relates to novel compounds of Formula I: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
摘要翻译: 本发明涉及式I的新化合物:其中A,Y,R 1,R 2和下标b各自具有本文所述的含义,式I化合物和立体异构体,几何异构体,互变异构体,溶剂合物,代谢物,同位素,药学上 其可接受的盐或前药。 式I化合物及其药物组合物可用于治疗观察到NF-kB信号传导的不期望或过度活化的疾病和病症。
-
公开(公告)号:US20130217666A1
公开(公告)日:2013-08-22
申请号:US13768873
申请日:2013-02-15
申请人: Genentech, Inc.
IPC分类号: C07D513/04 , C07D498/04
CPC分类号: C07D498/04 , C07D487/04 , C07D498/00 , C07D498/12 , C07D513/04 , C07D519/00
摘要: The invention relates to novel compounds of Formula I: wherein A1, A2, A3, A4, A5, A6, R2, R4, R5, R6, R7, R8 and subscripts m and n each has the meaning as described herein. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
-
-